Study of Alirocumab (REGN727/SAR236553) added-on to Rosuvastatin Versus Other Lipid Modifying Treatments (LMT) (ODYSSEY OPTIONS II)
A phase 3 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 305 participants.
Also called NCT01730053
- Study
- In this atlas
Overview
- Design
- Interventional study; randomized; quadruple masking; primary purpose treatment
- Phase
- Phase 3
- Enrolled
- 305 participants
- Sponsor
- Registry
-
NCT01730053
-
- Other papers using this trial's data
- Efficacy and safety of adding alirocumab to rosuvastatin versus adding ezetimibe or doubling the rosuvastatin dose in high cardiovascular-risk patients: The ODYSSEY OPTIONS II randomized trial
- Started
- (actual)
- Primary completion
- (actual)
- Completion
- (actual)
- Results first posted
- Countries
- United States, Australia, Canada, France, Germany, Italy, Mexico, Spain, United Kingdom
- Registry status
- Completed
Technical summary
Registry record NCT01730053. Randomized; quadruple masking; primary purpose treatment. Start 2012-11-30 (actual); primary completion 2014-04-30 (actual). Results posted on 2015-10-28.
The registry's words
Labels as the registry gives them, not rewritten.
- Brief title
- Study of Alirocumab (REGN727/SAR236553) added-on to Rosuvastatin Versus Other Lipid Modifying Treatments (LMT) (ODYSSEY OPTIONS II)
- Condition
- Hypercholesterolemia
- Intervention (Drug)
- Alirocumab
- Intervention (Drug)
- Rosuvastatin
- Intervention (Drug)
- Ezetimibe
- Intervention (Drug)
- Placebo
- Lead sponsor
- Regeneron Pharmaceuticals
- Collaborator
- Sanofi
Record details
- Record id
cardio:ct-nct01730053- Content hash
15c937967ca9a60985800838206dcc6b3eb25e5eb24c831155eb9516b81dec8e